COMPARISON OF INTRACERVICAL LAMINARIA PLUS VAGINAL MISOPROSTOL AND VAGINAL MISOPROSTOL ONLY WITH VARIABLE DOSAGES FOR MEDICAL ABORTION WITHIN 12 HOURS

Jae Eun Shin, MD, Ji Young Kwon, MD, Young Lee, MD, Jong Chul Shin, MD, In Yang Park, MD
Department of Obstetrics and Gynecology, The Catholic University of Korea School of Medicine, Seoul, Korea

Objective
To compare the effectiveness of intracervical laminaria plus vaginal misoprostol and vaginal misoprostol only with variable dosages by analyzing the rate of spontaneous gestational sac expulsion for medical abortion within 12 hours.

Methods
This study was performed in 94 patients for missed abortion at Department of Obstetrics and Gynecology, St. Paul’s Hospital, the Catholic University of Korea for 5 years (2004-2008). Forty seven patients were managed with laminaria insertion and intravaginal misoprostol 200 μg, 400 μg, or 800 μg at admission or outpatient clinic. The others were treated with only misoprostol at the same dose. We analyzed the rate of spontaneous expulsion of gestational sac within 12 hours.

Results
In non-laminaria group, spontaneous expulsion rate increased according to the doses of misoprostol (4.2%, 37.5%, and 33.3%, in 200 μg, 400 μg, and 800 μg, respectively, P=0.028). Between groups with the same misoprostol doses, no difference was observed in the spontaneous expulsion of the fetal sac within 12 hours according to the use of laminaria. On multivariate logistic regression analysis, factors that were associated significantly and independently with spontaneous expulsion of conceptus were misoprostol ≥400 μg and gestational age.

Conclusion
Treatment of missed abortion with 400 or 800 μg misoprostol vaginally is safe and acceptable method, and reduced the number of surgical interventions.

Keywords: Misoprostol; Laminaria; Missed abortion; Pregnancy
tion [3]. However, PGE$_2$ is expensive, and is not easy to be stored because of its chemical instability at room temperature. Moreover, it is accompanied with many gastrointestinal and cardiovascular side effects [4,5]. Recently emerging misoprostol, which is a synthetic derivative of PGE$_1$, has been used as a drug for duodenal ulcer, but is extended to be used in obstetric field, such as induction of labor and abortion, because it induces cervical dilatation and uterine contraction [6,7]. In addition, it is inexpensive and storable at room temperature, and causes fewer side effects [6,7]. Much research has been carried out to define the most effective and best tolerated dosage and route of administration, but previous studies have reported its success rate mostly within 24 hours [8,9]. In this study, we compared the effectiveness of intracervical laminaria plus vaginal misoprostol and vaginal misoprostol only with variable dosages by analyzing the rate of spontaneous gestational sac expulsion for medical abortion within 12 hours.

**Materials and Methods**

This study was conducted through analyzing medical records retrospectively, and the subjects were patients that visited the hospital for missed abortion in the 1st trimester and terminated pregnancy with medical management during five years (January 1, 2004–December 31, 2008). During the period, a total of 103 patients visited for missed abortion as principal diagnosis, and were randomly administered different doses of misoprostol and/or laminaria. Exclusion criteria were inevitable abortion or incomplete abortion, administration of 600 μg misoprostol vaginally, and oral administration of misoprostol. A total of 94 patients were included in the final analysis. They were divided into the group with laminaria inserted and that without, and each group was subdivided into three groups according to misoprostol dose (200 μg, 400 μg, and 800 μg).

In our hospital, misoprostol and/or laminaria were inserted vaginally in the evening of admission day, and after 12 hours on the next morning the expulsion of the fetal sac was confirmed by ultrasound. If the gestational sac was expelled spontaneously, the patient was discharged, and if not, curettage was performed. After that, patients were followed up after 1 week. We analyzed the fetal sac and embryo size to the accurate gestational age, and accompanying symptoms such as bleeding and low abdominal pain. In order to compare the effectiveness between the treatment

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Misoprostol 200 μg</th>
<th>Misoprostol 400 μg</th>
<th>Misoprostol 800 μg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-laminaria group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients (n)</td>
<td>24</td>
<td>8</td>
<td>15</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>32.3 ± 5.1</td>
<td>32.4 ± 4.2</td>
<td>34.7 ± 4.9</td>
</tr>
<tr>
<td>Gestational age (day)</td>
<td>61.8 ± 15.8</td>
<td>52.4 ± 12.8</td>
<td>66.8 ± 15.8</td>
</tr>
<tr>
<td>Gravida (n)</td>
<td>1.7 ± 1.3</td>
<td>1.8 ± 1.4</td>
<td>2.0 ± 2.1</td>
</tr>
<tr>
<td>Parity (n)</td>
<td>0.5 ± 0.7</td>
<td>0.6 ± 0.7</td>
<td>0.6 ± 0.9</td>
</tr>
<tr>
<td>Cesarean delivery history (n)</td>
<td>4</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Laminaria group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients (n)</td>
<td>27</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>30.1 ± 4.4</td>
<td>32.6 ± 6.7</td>
<td>29.2 ± 3.3</td>
</tr>
<tr>
<td>Gestational age (day)</td>
<td>65.4 ± 17.4</td>
<td>93.7 ± 26.7</td>
<td>91.3 ± 27.4</td>
</tr>
<tr>
<td>Gravida (n)</td>
<td>1.3 ± 1.6</td>
<td>2.2 ± 1.8</td>
<td>0.7 ± 0.8</td>
</tr>
<tr>
<td>Parity (n)</td>
<td>0.6 ± 0.7</td>
<td>0.6 ± 0.8</td>
<td>0.3 ± 0.5</td>
</tr>
<tr>
<td>Cesarean delivery history (n)</td>
<td>6</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

$^a$P-value<0.05.
methods, we reviewed age, gestational age, and prior pregnancy history, such as gravida, parity, and cesarean delivery history. Statistical analysis was used by XLSTAT ver. 2011.2.06 (Addinsoft, New York, NY, USA), and comparative analysis was performed by chi-square test for differences in qualitative variables and Student t-test for differences in continuous variables. A multivariate logistic regression model was constructed to identify independent risk factors associated with spontaneous expulsion rate and to control for confounders. Odds ratios and their 95% confidence interval were computed. Statistical significance was accepted if P-value<0.05.

Results

Of the 94 pregnant women who visited for therapeutic pregnancy termination due to missed abortion, 47 had both the insertion of laminaria and the vaginal insertion of misoprostol, and the dose of misoprostol was 200 μg in 27 of them, 400 μg in 10, and 800 μg in 10. In addition, 47 patients had only the vaginal insertion of misoprostol, and the dose of misoprostol was 200 μg in 24 of them, 400 μg in 8, and 800 μg in 15.

Maternal characteristic were analyzed in Table 1. In comparison with groups of different dosages of misoprostol, patients were not statistically different from each other in respect to age (31 years, 31 years, and 32 years, in 200 μg, 400 μg, and 800 μg, respectively, P=0.245), gravida (1, 2, and 1, in 200 μg, 400 μg, and 800 μg, respectively, P=0.585), parity (0.6, 0.6, and 0.5, in 200 μg, 400 μg, and 800 μg, respectively, P=0.851) and cesarean delivery history (10, 1, and 3, in 200 μg, 400 μg, and 800 μg, respectively, P=0.317). In gestational age, patients with 200 μg of misoprostol were lower than women with 400 μg and 800 μg (64 days, 75 days, and 77 days, in 200 μg, 400 μg, and 800 μg, respectively, P=0.027). In addition, these patients were divided into two groups according to the use of laminaria, and each group was subdivided into the 200 μg group, the 400 μg group, and the 800 μg group according to misoprostol dose. Table 1 shows the maternal age, gestational age, and prior pregnancy history, and statistically significant differences were observed in gestational age between the 400 μg groups, and age and gestational age between the 800 μg groups. No other statistical difference was observed.

We compared symptoms on admission such as vaginal bleeding and low abdominal pain among the groups, and found no significant difference (Table 2). In addition, ultrasonographic findings were compared in terms of gestational sac size, embryo size, and the presence of hematoma, and no difference was observed among the groups. In comparison with groups of different dos-

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Non-laminaria group</th>
<th>Laminaria group</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misoprostol 200 μg Patients (n)</td>
<td>24</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Vaginal bleeding (n)</td>
<td>15</td>
<td>11</td>
<td>0.121</td>
</tr>
<tr>
<td>Abdominal pain (n)</td>
<td>4</td>
<td>5</td>
<td>0.863</td>
</tr>
<tr>
<td>Gestational sac size (mm)</td>
<td>32.0 ± 18.4</td>
<td>28.4 ± 17.8</td>
<td>0.360</td>
</tr>
<tr>
<td>Embryo size (mm)</td>
<td>13.6 ± 11.8</td>
<td>11.0 ± 12.1</td>
<td>0.345</td>
</tr>
<tr>
<td>Subchorionic hematoma (n)</td>
<td>6</td>
<td>2</td>
<td>0.085</td>
</tr>
<tr>
<td>Misoprostol 400 μg Patients (n)</td>
<td>8</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Vaginal bleeding (n)</td>
<td>3</td>
<td>5</td>
<td>0.596</td>
</tr>
<tr>
<td>Abdominal pain (n)</td>
<td>2</td>
<td>1</td>
<td>0.396</td>
</tr>
<tr>
<td>Gestational sac size (mm)</td>
<td>30.5 ± 14.8</td>
<td>39.0 ± 21.6</td>
<td>0.583</td>
</tr>
<tr>
<td>Embryo size (mm)</td>
<td>17.0 ± 7.2</td>
<td>24.4 ± 26.2</td>
<td>0.643</td>
</tr>
<tr>
<td>Subchorionic hematoma (n)</td>
<td>1</td>
<td>0</td>
<td>0.250</td>
</tr>
<tr>
<td>Misoprostol 800 μg Patients (n)</td>
<td>15</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Vaginal bleeding (n)</td>
<td>8</td>
<td>3</td>
<td>0.250</td>
</tr>
<tr>
<td>Abdominal pain (n)</td>
<td>3</td>
<td>3</td>
<td>0.566</td>
</tr>
<tr>
<td>Gestational sac size (mm)</td>
<td>29.3 ± 20.4</td>
<td>25.0 ± 10.2</td>
<td>0.752</td>
</tr>
<tr>
<td>Embryo size (mm)</td>
<td>12.8 ± 9.6</td>
<td>16.7 ± 14.5</td>
<td>0.759</td>
</tr>
<tr>
<td>Subchorionic hematoma (n)</td>
<td>2</td>
<td>2</td>
<td>0.656</td>
</tr>
</tbody>
</table>
Ages of misoprostol, patients were not statistically different from each other in respect to vaginal bleeding (26, 8, and 11, in 200 μg, 400 μg, and 800 μg, respectively, P=0.805), abdominal pain (9, 3, and 6, in 200 μg, 400 μg, and 800 μg, respectively, P=0.769), gestational sac size (29 mm, 34 mm and 29 mm, in 200 μg, 400 μg, and 800 μg, respectively, P=0.959), embryo size (12 mm, 21 mm and 14 mm, in 200 μg, 400 μg, and 800 μg, respectively, P=0.103), and subchorionic hematoma (8, 1, and 4, in 200 μg, 400 μg and 800 μg, respectively, P=0.527).

Spontaneous expulsion rate of conceptus within 12 hours was analyzed in Table 3. In non-laminaria group, spontaneous expulsion rates increased according to the doses of misoprostol (4.2%, 37.5%, and 33.3%, in 200 μg, 400 μg, and 800 μg, respectively, P=0.028). In laminaria group, spontaneous expulsion rates were higher in the 400 μg, and 800 μg subgroups than 200 μg subgroup, but not significant statistically (7.4%, 20%, and 30%, in 200 μg, 400 μg, and 800 μg, respectively, P=0.077). Between groups with the same misoprostol dose, no difference was observed in the spontaneous expulsion of the fetal sac within 12 hours according to the use of laminaria.

On multivariate logistic regression analysis, factors that were associated significantly and independently with spontaneous expulsion of conceptus were misoprostol ≥400 μg and gestational age (Table 4). Laminaria insertion, previous abortion history and previous vaginal delivery were unrelated to increased risk of spontaneous expulsion. No one visited emergency room or needed hospitalization for abdominal pain, vaginal bleeding or infection within 1 week of follow-up. No one required transfusion or additional curettage.

**Discussion**

For medical abortion, it is known that combined regimen of mifepristone (antiprogesterone) and prostaglandin is more effective than prostaglandin alone, but misoprostol alone is widely used in some parts of the world, including Korea, where mifepristone is not available [10]. The reported complete abortion rate for misoprostol alone varies between 33% to 60% for single dose and 93% for repeat doses [10]. The success rates of medically-treated first trimester miscarriages varied according to dosages and route.
of misoprostol, the ultrasonographic definitions of pregnancy failure, time of assessment, and the criteria for success [11]. Of the different routes of misoprostol administration, vaginal route appears to be superior to oral, sublingual and buccal administration in terms of efficacy, and has fewer side effects when compared to other routes [11]. A regimen of 800 μg of misoprostol administered vaginally every 24 hours for up to three doses achieved complete abortion rates in 88% to 91% of women who were <8 weeks pregnant. This regimen takes several days [12,13]. Another regimen using 800 μg of misoprostol (administered vaginally) as an initial dose followed by 400 μg of misoprostol (administered orally) every 3 hours for three to four doses achieved complete abortion rates in 70%-85% of women [14,15].

In case pregnancy termination is performed for missed abortion in the 1st trimester, the first consideration is whether to use drug treatment or surgical treatment, and also it should be considered how to reduce the patient’s anxiety and guilty feeling. In order to relieve them, we need to minimize the number of hospital visits or hospital stay and this consideration is also meaningful in terms of expenses [16,17]. According to previous reports, when misoprostol was administered the probability of the successful spontaneous expulsion of the fetal sac within 24 hours was around 80%, but it is practically difficult to wait for 24 hours after the administration of the drug [18]. One of the reasons is that outpatient follow-up after the vaginal insertion of misoprostol may result in abdominal pain or vaginal bleeding at an unpredictable time and this may cause many troubles to the patient and guardian including admission to the emergency room. For these reasons, the authors compared patients who had both the insertion of laminaria and the vaginal insertion of misoprostol with those who had only the vaginal insertion of misoprostol in order to see the probability of the spontaneous expulsion of the fetal sac within 12 hours and which treatment is more successful with less pain and discomfort. In our study, all women with a spontaneous expulsion, which was no gestational sac in endometrium confirmed by ultrasound, did not need to undergo additional surgical management. It is known that if no gestational sac is present, in the absence of heavy bleeding, intervention in most women is unnecessary [19]. This is true even when, as is common, the uterus contains sonographically evident debris [19].

Misoprostol is known as a safe agent for early pregnancy failure, but precautions should be taken into consideration in some complications and side-effects. Diarrhea is the major adverse reaction, but it is usually mild and self-limiting [20]. Fever and chills have also been reported, but are more associated with higher doses in the third trimester or immediate postpartum period [20]. In addition, medical methods are associated with a longer duration of bleeding than surgical methods [10]. Another concern is the risk of uterine rupture, especially in women with a previous uterine scar. Reports of uterine rupture are rare in first trimester medical abortion, but the risk seems to increase with gestation [20,21]. Exposure to misoprostol in early pregnancy has been associated with multiple congenital defects, therefore, counsel the women on the risk of fetal abnormality if the pregnancy is continued after exposure to misoprostol [20,22].

According to the results of this analysis, the use of laminaria did not have an effect on the spontaneous expulsion of the fetal sac. In addition, among those who had the vaginal insertion of misoprostol, the success rate was highest when the misoprostol dose was 400 μg and 800 μg. In conclusion, the vaginal insertion of misoprostol was safe and acceptable method for therapeutic pregnancy termination for missed abortion in the 1st trimester, and reduced the number of surgical intervention.

References


gual misoprostol regimens for surgical termination of first tri-
mester pregnancies: a prospective randomized trial. J Reprod
8. Ngai SW, To WK, Lao T, Ho PC. Cervical priming with oral
misoprostol in pre-labor rupture of membranes at term. Obstet
Gynecol 1996;87:923-6.
9. Scheepers HC, van Erp EJ, van den Bergh AS. Use of misopros-
stol in first and second trimester abortion: a review. Obstet
Gynecol Surv 1999;54:592-600.
Campana A. Medical methods for first trimester abortion. Co-
11. Vejborg TS, Nilas L, Rørbye C. Medical management of first
trimester miscarriage according to ultrasonographic findings.
prospective randomized, double-blinded, placebo-controlled
trial comparing mifepristone and vaginal misoprostol to vagi-
nal misoprostol alone for elective termination of early preg-
13. Zikopoulos KA, Papanikolaou EG, Kalantaridou SN, Tsanadis
GD, Plachouras NI, Dalkalitis NA, et al. Early pregnancy ter-
munication with vaginal misoprostol before and after 42 days
14. Singh K, Fong YF, Dong F. A viable alternative to surgical
vacuum aspiration: repeated doses of intravaginal misoprostol
over 9 hours for medical termination of pregnancies up to
eight weeks. BJOG 2003;110:175-80.
15. Tang OS, Wong KS, Tang LC, Ho PC. Pilot study on the use of
repeated doses of misoprostol in termination of pregnancy at
16. Li YT, Hsieh JC, Hou GQ, Chen TH, Chu YC, Lin TC, et al. Simul-
taneous use of mifepristone and misoprostol for early preg-
17. Ngoc NT, Blum J, Raghavan S, Nga NT, Dabash R, Diop A,
et al. Comparing two early medical abortion regimens:
mifepristone+misoprostol vs. misoprostol alone. Contracep-
tion 2011;83:410-7.
J. Comparison of sublingual versus vaginal misoprostol for
second-trimester pregnancy termination: a meta-analysis. Aust
Williams obstetrics. 23rd ed. New York: McGraw-Hill Profes-
sional; 2010.
20. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharma-
cokinetic profiles, effects on the uterus and side-effects. Int J
misoprostol and uterine rupture in the first trimester of preg-
22. Orioli IM, Castilla EE. Epidemiological assessment of misopros-
12시간 이내의 치료적 유산을 위한 자궁경부 내 라미나리아 및 미소프로스톨 병합투여와 미소프로스톨 단독요법의 비교

가톨릭대학교 의과대학 산부인과학학교실
신재은, 권지영, 이영, 신종철, 박인양

목적
임신 첫 삼분기 계류유산 치료에 있어 12시간 이내에 자연적으로 태낭이 배출되는 빈도를 분석함으로써 라미나리아와 미소프로스톨을 사
용하는 경우와 미소프로스톨만을 사용하는 경우의 효과를 비교하고자 하였다.

연구방법
최근 5년간 계류유산으로 진단받고 치료적 임신 종결을 시행받은 94명을 분석 대상으로 하여 후향적으로 분석하였으며, 이 중 47명은 라
미나리아를 사용하였으며 이들은 미소프로스톨 사용량에 따라 200 μg, 400 μg, 800 μg 군으로 각기 나누었으며 라미나리아를 사용하지
 않은 군도 같이 분류하였다. 각 군에서 치료 시행 후 12시간 이내에 태낭이 자연 배출되는 경우를 통계 분석하였다.

결과
라미나리아 사용하지 않은 그룹에서 자연배출 빈도는 미소프로스톨의 용량에 따라 증가하였다(각각 200 μg, 400 μg, 800 μg에서
4.2%, 37.5%과 33.3%, P=0.028). 같은 미소프로스톨 용량의 그룹 간 비교에서, 라미나리아 사용 여부에 따른 12시간 이내 자연배출의 빈
도는 차이가 없었다. 다변량 로지스틱 회귀 분석에 따르면 유산물의 자연 배출 빈도는 400 μg 용량 이상의 미소프로스톨과 임신 재태 연
령과 의미있고 독립적으로 관련이 있었다.

결론
계류유산 치료에 있어 잠대로 삽입하는 미소프로스톨은 효과적이고 안정적인 약제로 사용할 수 있으며, 12시간 이내 자연적으로 태낭이
배출되는 확률은 400 μg, 800 μg를 사용하는 경우 가장 높았다.

중심단어: 미소프로스톨, 라미나리아, 계류유산, 임신

KOREAN JOURNAL OF OBSTETRICS & GYNECOLOGY
KIOG Vol. 55, No. 4, 2012